![PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?](https://revive.gardp.org/wp-content/uploads/2018/06/GARDP_REVIVE_Poster_WH1_new-colours-scaled-1.jpg)
PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?
more![<br>Antibacterial drugs: Clinical development for non-developers </br> Part 1: Traditional development – tiers A and B](https://revive.gardp.org/wp-content/uploads/2018/06/GARDP_REVIVE_Poster_DS1_new-colours-scaled-1.jpg)
Antibacterial drugs: Clinical development for non-developers Part 1: Traditional development – tiers A and B
more![Coping with Preclinical Toxicology Challenges](https://revive.gardp.org/wp-content/uploads/2018/06/Screenshot.jpg)
Coping with Preclinical Toxicology Challenges
more![Drug Discovery Data Insights: Highly Accessible SAR Data is Transforming the Drug Discovery Informatics Landscape](https://revive.gardp.org/wp-content/uploads/2018/05/SAR-structures-500wEdge_edited.jpg)
Drug Discovery Data Insights: Highly Accessible SAR Data is Transforming the Drug Discovery Informatics Landscape
more![Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?](https://revive.gardp.org/wp-content/uploads/2018/05/ECCMID-Rex-slide_outline.png)